GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » Pre-Tax Income

Cingulate (Cingulate) Pre-Tax Income : $-22.50 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Cingulate Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cingulate's pretax income for the three months ended in Mar. 2024 was $-2.97 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-22.50 Mil. Cingulate's pretax margin was %.


Cingulate Pre-Tax Income Historical Data

The historical data trend for Cingulate's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate Pre-Tax Income Chart

Cingulate Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
-11.55 -7.18 -20.71 -17.68 -23.54

Cingulate Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.01 -6.62 -5.98 -6.94 -2.97

Competitive Comparison of Cingulate's Pre-Tax Income

For the Biotechnology subindustry, Cingulate's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cingulate's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cingulate's Pre-Tax Income falls into.



Cingulate Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cingulate's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-22.759+0+-0.776+0+0
=-23.54

Cingulate's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-2.948+0+-0.024+0+0
=-2.97

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cingulate  (NAS:CING) Pre-Tax Income Explanation

Cingulate's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-2.972/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cingulate Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cingulate's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Cingulate (Cingulate) Business Description

Traded in Other Exchanges
N/A
Address
1901 W. 47th Place, Kansas, KS, USA, 66205
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Executives
Jennifer L. Callahan officer: Corporate Controller C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth director, 10 percent owner C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer director, 10 percent owner, officer: Chief Executive Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon officer: EVP & General Counsel C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers officer: EVP & Chief Operating Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum director C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros director 2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G officer: EVP & Chief Financial Officer C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher director 275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy director 2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves director C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva officer: EVP & Chief Science Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams officer: EVP & Chief Medical Officer C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc 10 percent owner 1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205